866-997-4948(US-Canada Toll Free)

Metastatic Melanoma Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 375 Pages


Global Markets Directs, \'Metastatic Melanoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. 

Metastatic Melanoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Melanoma.
  • A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Metastatic Melanoma Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Metastatic Melanoma 13
Metastatic Melanoma Therapeutics under Development by Companies 15
Metastatic Melanoma Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Metastatic Melanoma Therapeutics Products under Development by Companies 28
Metastatic Melanoma Therapeutics Products under Investigation by Universities/Institutes 34
Companies Involved in Metastatic Melanoma Therapeutics Development 37
Bristol-Myers Squibb Company 37
F. Hoffmann-La Roche Ltd. 38
Vical Incorporated 39
Sanofi-Aventis 40
Eli Lilly and Company 41
Viralytics Ltd. 42
GlaxoSmithKline plc 43
Genentech, Inc. 44
Antigenics, Inc. 45
Oxford BioMedica plc 46
Delcath Systems, Inc. 47
ZIOPHARM Oncology, Inc. 48
Millennium Pharmaceuticals, Inc. 49
Novartis AG 50
Eisai Co., Ltd. 51
Ono Pharmaceutical Co., Ltd. 52
Takara Holdings Inc. 53
Celgene Corporation 54
Incyte Corporation 55
Merck KGaA 56
Hana Biosciences, Inc. 57
Hemispherx Biopharma, Inc. 58
Celldex Therapeutics, Inc. 59
Lorus Therapeutics Inc 60
Marshall Edwards, Inc. 61
AVAX Technologies, Inc. 62
Northwest Biotherapeutics, Inc. 63
Osta Biotechnologies Inc. 64
Tolerx, Inc. 65
Progen Pharmaceuticals Limited 66
Provectus Pharmaceuticals, Inc. 67
Morphotek, Inc. 68
Colby Pharmaceutical Company 69
DNA Therapeutics S.A. 70
Biotecnol SA 71
Philogen S.p.A. 72
siRNAsense AS 73
Curacyte AG 74
BioNumerik Pharmaceuticals, Inc. 75
Cytheris SA 76
Deciphera Pharmaceuticals, LLC 77
Affichem 78
Omeros Corporation 79
Immunocore Limited. 80
AB Science 81
CureTech Ltd. 82
WntResearch AB 83
Life Science Pharmaceuticals, Incorporated 84
Cancer Therapeutics CRC Pty Ltd 85
Targa Therapeutics Corp. 86
Cytavis Biopharma GmbH 87
Polaris Group 88
Gradalis Inc. 89
Lipotek Pty Ltd 90
Metastatic Melanoma Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Combination Products 92
Assessment by Route of Administration 93
Assessment by Molecule Type 95
Drug Profiles 98
nilotinib - Drug Profile 98
darleukin - Drug Profile 100
denenicokin - Drug Profile 102
CDX-1127 - Drug Profile 104
trametinib - Drug Profile 105
velimogene aliplasmid - Drug Profile 108
GDC-0973 - Drug Profile 110
vemurafenib - Drug Profile 111
vemurafenib - Drug Profile 114
vemurafenib - Drug Profile 117
paclitaxel albumin-bound - Drug Profile 120
pimasertib - Drug Profile 122
TRX-518 - Drug Profile 124
ramucirumab - Drug Profile 126
MEK-162 - Drug Profile 130
vincristine sulfate - Drug Profile 133
M-Vax - Drug Profile 136
PI-88 - Drug Profile 138
CXCR4 Antibody - Drug Profile 140
Provecta - Drug Profile 141
Triphendiol - Drug Profile 143
MORAb-004 - Drug Profile 144
GM-CT-01 - Drug Profile 146
CPC-410 - Drug Profile 148
CYT-99 007 - Drug Profile 149
CYT-107 - Drug Profile 150
pidilizumab - Drug Profile 153
P-276 - Drug Profile 155
CVA-21 - Drug Profile 157
Hemoximer - Drug Profile 160
HF-10 - Drug Profile 162
aviscumine - Drug Profile 163
CYC-381 - Drug Profile 165
ecromeximab - Drug Profile 166
tamoxifen citrate - Drug Profile 167
BreMel/TNF-a - Drug Profile 168
Disulfiram + Arsenic Trioxide - Drug Profile 169
LOC-paclitaxel - Drug Profile 170
Alpha-Gal Glycosphingolipids - Drug Profile 171
B7-DC Xab Plasma Therapy - Drug Profile 172
Adenovirus CCL 21 Transduced MART-1/gp100 Peptide Pulsed Dendritic Cells Matured Using Cytokines - Drug Profile 173
melphalan + Hyperthermia - Drug Profile 174
Melphalan + Chemosaturation Therapy - Drug Profile 175
AF-122 - Drug Profile 177
ADI-PEG 20 - Drug Profile 178
Box-5 - Drug Profile 181
TAK-733 - Drug Profile 182
PI-88 + [dacarbazine] - Drug Profile 183
Darleukin + Dacarbazine - Drug Profile 184
Lipovaxin-MM - Drug Profile 185
GSK-2132231-A - Drug Profile 186
masitinib - Drug Profile 188
Dendritic Cell Vaccine Therapy + [Autologous Lymphocytes] - Drug Profile 190
ALVAC ESO-1 Vaccine + Anti-NY ESO-1 TCR-Gene Engineered Lymphocyte + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 192
astuprotimut-R - Drug Profile 193
rebastinib - Drug Profile 195
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 197
cositecan - Drug Profile 198
nivolumab - Drug Profile 200
VCL-IM01 - Drug Profile 203
OB-28 - Drug Profile 204
4-Peptide Melanoma Vaccine - Drug Profile 205
nilotinib - Drug Profile 206
GSK-2132231A + [dacarbazine] - Drug Profile 207
bevacizumab + [temozolomide] - Drug Profile 208
dabrafenib + trametinib - Drug Profile 209
dabrafenib + trametinib - Drug Profile 211
lenvatinib + [dacarbazin] - Drug Profile 213
denenicokin - Drug Profile 215
GSK-2302025-A - Drug Profile 216
dabrafenib - Drug Profile 217
MVAX + [aldesleukin] - Drug Profile 219
Anti-NY ESO-1 TCR-Gene Engineered Autologous Lymphocytes + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 220
IMCgp100 - Drug Profile 221
F5 TCR transgenic cells + MART-1 peptide pulsed dendritic cells + [cyclophosphamide] + [fludarabine] - Drug Profile 223
Dendritic Cells Vaccine - Drug Profile 225
MART-1 26-35 + MART-1 27-35 + 27-35 (27L)MART-1 + [aldesleukin] + [GP-100 209-217 ] + [Montanide ISA 51] - Drug Profile 226
cyclophosphamide + vinblastine sulfate + [dacarbazine] - Drug Profile 228
indisulam - Drug Profile 229
Melan-A VLP Vaccine + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 230
Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 232
Autologous Lymphocyte + Fowlpox Gp100 Vaccine + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] + [G-CSF] - Drug Profile 233
Anti-MART-1 F5 TCR PBL + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] + [MART-1: 26-35(27L) Peptide] + [Montanide ISA 51 VG] + Radiation Therapy - Drug Profile 235
bevacizumab + [carboplatin] + [everolimus] + [paclitaxel] - Drug Profile 237
GSK-2241658-A - Drug Profile 239
mRNA Transfected Dendritic Cell Vaccine + [cisplatin] - Drug Profile 240
Anti-gp 100:154 TCR PBL + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] + [gp100:154-162 Peptide] + [Montanide ISA 51 VG] + Radiation Therapy - Drug Profile 241
rucaparib + [temozolomide] - Drug Profile 243
DPK-M3 - Drug Profile 244
DPK-M1 - Drug Profile 245
GDC-0973 + [vemurafenib] - Drug Profile 246
Dendritic Cell Vaccines - Drug Profile 248
L19 Tumor Necrosis Factor Alpha + [melphalan] - Drug Profile 249
DNA IL-12 - Drug Profile 250
MAGE-A3 + [aldesleukin] + [AS15] - Drug Profile 252
scFvMel/rGel - Drug Profile 254
DC-IL-12 - Drug Profile 255
MLN-2480 - Drug Profile 257
BO-110 - Drug Profile 259
RG-7446 - Drug Profile 260
GPR19 Antagonist - Drug Profile 261
bevacizumab + [vemurafenib] - Drug Profile 262
Pbi-shRNA STMN1 LP - Drug Profile 263
Contego - Drug Profile 264
Hi-8 MEL - Drug Profile 265
RG-7636 - Drug Profile 266
MEDI-6469 - Drug Profile 267
INCB-024360 + [ipilimumab] - Drug Profile 269
Autologous T Cells Expressing Enhanced TCRs Specific For MAGE-A3/A6/B18 or NYESO-1/LAGE - Drug Profile 270
Drug Targeting FAK, FLT3 And VEGFR3 - Drug Profile 272
MORAb-050 - Drug Profile 274
ADI-PEG-20 + cisplatin - Drug Profile 275
Bivalent Bispecific Tribody - Drug Profile 277
pazopanib hydrochloride + [paclitaxel] - Drug Profile 278
M-200 - Drug Profile 279
CM-10 - Drug Profile 280
SAR-260301 - Drug Profile 281
SAR-260301 + Vemurafenib - Drug Profile 282
DT-01 - Drug Profile 283
bortezomib + interferon-alpha 2b - Drug Profile 285
SPACE-siRNA - Drug Profile 286
PEPA - Drug Profile 287
Endothelin Receptor Antagonist - Drug Profile 288
Tissue Factor Project - Drug Profile 289
Metastatic Melanoma Therapeutics Drug Profile Updates 290
Metastatic Melanoma Therapeutics Discontinued Products 349
Metastatic Melanoma Therapeutics - Dormant Products 350
Metastatic Melanoma Product Development Milestones 357
Featured News & Press Releases 357

Appendix 366
Methodology 366
Coverage 366
Secondary Research 366
Primary Research 366
Expert Panel Validation 366
Contact Us 367
Disclaimer 367

List of Table


Number of Products Under Development for Metastatic Melanoma, H1 2013 21
Products under Development for Metastatic Melanoma Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2013 30
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 31
Comparative Analysis by Late Stage Development, H1 2013 32
Comparative Analysis by Mid Clinical Stage Development, H1 2013 33
Comparative Analysis by Early Clinical Stage Development, H1 2013 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 35
Products under Development by Companies, H1 2013 36
Products under Development by Companies, H1 2013 (Contd..1) 37
Products under Development by Companies, H1 2013 (Contd..2) 38
Products under Development by Companies, H1 2013 (Contd..3) 39
Products under Development by Companies, H1 2013 (Contd..4) 40
Products under Development by Companies, H1 2013 (Contd..5) 41
Products under Investigation by Universities/Institutes, H1 2013 42
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 43
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 44
Bristol-Myers Squibb Company, H1 2013 45
F. Hoffmann-La Roche Ltd., H1 2013 46
Vical Incorporated, H1 2013 47
Sanofi-Aventis, H1 2013 48
Eli Lilly and Company, H1 2013 49
Viralytics Ltd., H1 2013 50
GlaxoSmithKline plc, H1 2013 51
Genentech, Inc., H1 2013 52
Antigenics, Inc., H1 2013 53
Oxford BioMedica plc, H1 2013 54
Delcath Systems, Inc., H1 2013 55
ZIOPHARM Oncology, Inc., H1 2013 56
Millennium Pharmaceuticals, Inc., H1 2013 57
Novartis AG, H1 2013 58
Eisai Co., Ltd., H1 2013 59
Ono Pharmaceutical Co., Ltd., H1 2013 60
Takara Holdings Inc., H1 2013 61
Celgene Corporation, H1 2013 62
Incyte Corporation, H1 2013 63
Merck KGaA, H1 2013 64
Hana Biosciences, Inc., H1 2013 65
Hemispherx Biopharma, Inc., H1 2013 66
Celldex Therapeutics, Inc., H1 2013 67
Lorus Therapeutics Inc, H1 2013 68
Marshall Edwards, Inc., H1 2013 69
AVAX Technologies, Inc., H1 2013 70
Northwest Biotherapeutics, Inc., H1 2013 71
Osta Biotechnologies Inc., H1 2013 72
Tolerx, Inc., H1 2013 73
Progen Pharmaceuticals Limited, H1 2013 74
Provectus Pharmaceuticals, Inc., H1 2013 75
Morphotek, Inc., H1 2013 76
Colby Pharmaceutical Company, H1 2013 77
DNA Therapeutics S.A., H1 2013 78
Biotecnol SA, H1 2013 79
Philogen S.p.A., H1 2013 80
siRNAsense AS, H1 2013 81
Curacyte AG, H1 2013 82
BioNumerik Pharmaceuticals, Inc., H1 2013 83
Cytheris SA, H1 2013 84
Deciphera Pharmaceuticals, LLC, H1 2013 85
Affichem, H1 2013 86
Omeros Corporation, H1 2013 87
Immunocore Limited., H1 2013 88
AB Science, H1 2013 89
CureTech Ltd., H1 2013 90
WntResearch AB, H1 2013 91
Life Science Pharmaceuticals, Incorporated, H1 2013 92
Cancer Therapeutics CRC Pty Ltd, H1 2013 93
Targa Therapeutics Corp., H1 2013 94
Cytavis Biopharma GmbH, H1 2013 95
Polaris Group, H1 2013 96
Gradalis Inc., H1 2013 97
Lipotek Pty Ltd, H1 2013 98
Assessment by Monotherapy Products, H1 2013 99
Assessment by Combination Products, H1 2013 100
Assessment by Stage and Route of Administration, H1 2013 102
Assessment by Stage and Molecule Type, H1 2013 105
Metastatic Melanoma Therapeutics Drug Profile Updates 298
Metastatic Melanoma Therapeutics Discontinued Products 357
Metastatic Melanoma Therapeutics Dormant Products 358
Metastatic Melanoma Therapeutics Dormant Products (Contd..1) 359
Metastatic Melanoma Therapeutics Dormant Products (Contd..2) 360
Metastatic Melanoma Therapeutics Dormant Products (Contd..3) 361
Metastatic Melanoma Therapeutics Dormant Products (Contd..4) 362
Metastatic Melanoma Therapeutics Dormant Products (Contd..5) 363
Metastatic Melanoma Therapeutics Dormant Products (Contd..6) 364

List of Chart


Number of Products under Development for Metastatic Melanoma, H1 2013 21
Products under Development for Metastatic Melanoma Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 29
Late Stage Products, H1 2013 32
Mid Clinical Stage Products, H1 2013 33
Early Clinical Stage Products, H1 2013 34
Discovery and Pre-Clinical Stage Products, H1 2013 35
Assessment by Monotherapy Products, H1 2013 99
Assessment by Combination Products, H1 2013 100
Assessment by Route of Administration, H1 2013 101
Assessment by Stage and Route of Administration, H1 2013 102
Assessment by Molecule Type, H1 2013 103
Assessment by Stage and Molecule Type, H1 2013 104

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *